Related Experiment Video
Updated: May 10, 2026
06:59
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Exenatide once weekly: opportunities in the primary care setting
Jaime A Davidson1, Carla Nikkel, Michael Grimm
1Department of Medicine, Division of Endocrinology, Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. jaime.davidson@utsouthwestern.edu
Postgraduate Medicine
|June 11, 2013
Summary
Exenatide once weekly (EQW) offers effective type 2 diabetes management, lowering blood glucose and body weight with minimal hypoglycemia risk. This glucagon-like peptide-1 receptor agonist is suitable for primary care settings.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a global pandemic.
- Primary care physicians manage over 90% of T2DM patients in the US.
- Optimal T2DM treatment requires balancing glycemic control, weight management, cardiovascular risk, and hypoglycemia risk.
Purpose of the Study:
- To provide an overview of exenatide once weekly (EQW), a novel therapy for T2DM.
- To evaluate EQW's efficacy, safety, and place in primary care management of T2DM.
Main Methods:
- Review of clinical trials demonstrating EQW's efficacy and safety.
- Assessment of EQW's pharmacology, dosing, and tolerability.
- Consideration of patient perceptions and ease of use in primary care.
Main Results:
- EQW effectively lowers blood glucose levels in T2DM patients.
- EQW demonstrates significant body weight reduction.
- EQW is associated with a minimal risk of hypoglycemia.
Conclusions:
- Exenatide once weekly (EQW) is a valuable therapeutic option for T2DM.
- EQW offers continuous glycemic control with convenient once-weekly dosing.
- EQW presents a favorable profile for primary care physicians managing T2DM.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:15Non-Oral Extravascular Drug Absorption Routes
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more effectively...
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more effectively...
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...